Setup

Broadwood Partners forced CEO change at STAAR Surgical after accumulating $70M+ stake. Stock down 20% in a month (RSI 16.9), options IV at 5th percentile. Company just turned profitable: Q3 $0.47 EPS beat vs $0.30 est. Earnings Feb 10 — 8 days away.

The 8-K (Feb 2)

Item 5.02: Warren Foust (President/COO) and Deborah Andrews (CFO) appointed interim co-CEOs effective Feb 1, following activist-driven ouster of CEO Stephen Farrell via Jan 14 Cooperation Agreement. Global CEO search launched. Foust gets severance protection if passed over by Aug 1, 2026.

This filing contains no new alpha — it's execution of the publicly disclosed Jan 15 Cooperation Agreement. The CEO departure was telegraphed.

What's Interesting

Activist conviction: Broadwood bought $41M in Nov, $9.4M in Jan, plus $18M+ through 2025 — total $70M+ deployed while stock dropped 20%. That's real skin in the game.

Earnings inflection: -$0.51 → -$1.00 → -$0.13 → +$0.47. Company turned profitable Q3. Forward P/E 51× on $0.15 est EPS (growth story, not value).

Technical extremes: RSI 16.9 (deeply oversold). ATM IV 6.3% (5th percentile) — options pricing almost no vol despite activist situation + earnings in 8 days. 14.3% short interest.

Catalyst: Earnings Feb 10. Analyst consensus neutral (9 holds), mean target $23.36 (+23% upside from $18.95).

Questions to Answer

  1. What's Broadwood's thesis? Why pour $70M into an ophthalmic device company?
  2. ICL (implantable contact lens) fundamentals: TAM, growth rate, competitive position vs HROW and others?
  3. Why did earnings inflect Q3? Sustainable or one-time?
  4. What does the new CEO hire signal when announced?
  5. Why are options so cheap (5th %ile IV) into earnings with this setup?

Initial Take

The 8-K itself is noise. The setup is real: activist with $70M+ conviction, company inflecting to profitability, deeply oversold technicals, cheap options, earnings catalyst in 8 days. Worth a deep dive into ICL business fundamentals and whether Broadwood's valuation thesis has merit.

Not a recommendation yet — need to validate the earnings trajectory and understand the ICL competitive landscape. But the combination of activist alignment + cheap options + near-term catalyst = potentially interesting risk/reward.